Home
Market
FDA Removes Partial Clinical Hold on Gilead’s MDS and AML Magrolimab Studies
Market

FDA Removes Partial Clinical Hold on Gilead’s MDS and AML Magrolimab Studies

3 years ago No Comments

This post was originally published on this site

“This is a significant milestone for Gilead and, more importantly, for patients diagnosed with these cancers,” Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, said.

GILD shares are down 15% year-to-date.

Related Posts

About The Author

admin
More from this Author